Recent IPO Abpro Corporation recently went public, raising $69 million through an IPO. The funding from this public offering can signify potential growth and expansion opportunities for sales partnerships and collaborations.
Partnership Opportunities Abpro has formed strategic partnerships with global biopharmaceutical companies like Celltrion, creating avenues for joint product development. Leveraging these partnerships can open doors for sales of innovative treatments across different markets.
Innovative Therapies Development Abpro is actively developing novel bispecific antibody therapies in immuno-oncology, representing a cutting-edge approach in the industry. Sales professionals can explore opportunities to introduce these advanced therapies to healthcare providers and patients.
Technology Collaboration Collaborating with companies like NJCTTQ for technology advancement indicates a commitment to innovation. Sales teams can leverage these tech collaborations to highlight Abpro's advanced capabilities and attract potential clients seeking groundbreaking biotech solutions.
Expertise in Severe Diseases Abpro's focus on antibody therapeutics for severe diseases, particularly in immuno-oncology and ophthalmology, showcases expertise in critical healthcare areas. Sales representatives can use this specialization to position Abpro as a key player in addressing high-impact medical needs.
2.6K
$1B
2.9K$1B
73K$1B
66
5K$1B
512$50M$100M
283$50M$100M
565$100M$1B
201$50M$100MAbpro uses 8 technology products and services including WordPress, Microsoft Word, Microsoft Excel, and more. Explore Abpro 's tech stack below.
| Abpro Email Formats | Percentage |
| FLast@abpro.com | 49% |
| First@abpro.com | 1% |
| FLast@abpro.com | 49% |
| First@abpro.com | 1% |
Biotechnology ResearchMassachusetts, United States11-50 Employees
We're a biotech company dedicated to advancing antibody therapeutics for severe diseases. Focusing on immuno-oncology and ophthalmology, we leverage our proprietary DiversImmune® and MultiMab platforms to develop next-gen antibodies. Collaborating with global pharmaceutical and research partners, we're building a robust pipeline of innovative treatments. For more information, please visit https://abpro.com/
Company Overview
Funding & FinancialsAbpro has raised a total of $18M of funding over 3 rounds. Their latest funding round was raised on Jan 27, 2020 in the amount of $18M.
Abpro 's revenue is in the range of $10M
Funding & FinancialsAbpro has raised a total of $18M of funding over 3 rounds. Their latest funding round was raised on Jan 27, 2020 in the amount of $18M.
Abpro 's revenue is in the range of $10M
1-888-653-2347 
support@leadiq.com